Charles A. Lambert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charles A. Lambert has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alain Colige
Laboratory of Connective Tissues Biology, GIGA, Quartier Hôpital, University of Liège, Avenue Hippocrate 13, 4000 Liège, Belgium
2 shared publications - Adeline Deward
Laboratory of Virology and Immunology, GIGA-Signal Transduction, GIGA B34, University of Liège, avenue de l'Hôpital 1, 4000, Liège, Belgium.
1 shared publication Agnès Noël
Laboratory of Tumor and Development Biology
1 shared publicationAlain C. Colige
Laboratory of Connective Tissues Biology, 2Laboratory of Tumor and Development Biology, and 3Laboratory of Fundamental Virology and Immunology, Groupe Interdisciplinaire de Génoprotéomique Appliquée Research and Center for Research in Experimental Cancerology, University of Liège, B-4000 Liège, Belgium
1 shared publication- Benoit Chabot
Université de Sherbrooke, Faculté de médecine et des sciences de la santé Département de Microbiologie et d’Infectiologie, Sherbrooke, Canada
1 shared publication - Benoit Hennuy
GIGA Genomics Platform, University of Liège, avenue de l'Hôpital 1, 4000, Liège, Belgium.
1 shared publication
Latest Publications
- 1 October 2017
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 91, 84-97
Chemotherapy induces alternative transcription and splicing: Facts and hopes for cancer treatment
- 1 October 2017
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 91, 84-97
Chemotherapy induces alternative transcription and splicing: Facts and hopes for cancer treatment
- Open Access
- 7 April 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 227
Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis
Modification of splicing by chemotherapeutic drugs has usually been evaluated on a limited number of pre-mRNAs selected for their recognized or potential importance in cell proliferation or apoptosis. However, the pathways linking splicing alterations to the efficiency of cancer therapy remain unclear. Next-generation sequencing was used to analyse the transcriptome of breast carcinoma cells treated by cisplatin. Pharmacological inhibitors, RNA interference, cells deficient in specific signalling pathways, RT-PCR and FACS analysis were used to investigate how the anti-cancer drug cisplatin affected alternative splicing and the cell death pathway. We identified 717 splicing events affected by cisplatin, including 245 events involving cassette exons. Gene ontology analysis indicates that cell cycle, mRNA processing and pre-mRNA splicing were the main pathways affected. Importantly, the cisplatin–induced splicing alterations required class I PI3Ks P110β but not components such as ATM, ATR and p53 that are involved in the DNA damage response. The siRNA-mediated depletion of the splicing regulator SRSF4, but not SRSF6, expression abrogated many of the splicing alterations as well as cell death induced by cisplatin. Many of the splicing alterations induced by cisplatin are caused by SRSF4 and they contribute to apoptosis in a process requires class I PI3K.
- 7 April 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 227
Open AccessRole of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis
Modification of splicing by chemotherapeutic drugs has usually been evaluated on a limited number of pre-mRNAs selected for their recognized or potential importance in cell proliferation or apoptosis. However, the pathways linking splicing alterations to the efficiency of cancer therapy remain unclear. Next-generation sequencing was used to analyse the transcriptome of breast carcinoma cells treated by cisplatin. Pharmacological inhibitors, RNA interference, cells deficient in specific signalling pathways, RT-PCR and FACS analysis were used to investigate how the anti-cancer drug cisplatin affected alternative splicing and the cell death pathway. We identified 717 splicing events affected by cisplatin, including 245 events involving cassette exons. Gene ontology analysis indicates that cell cycle, mRNA processing and pre-mRNA splicing were the main pathways affected. Importantly, the cisplatin–induced splicing alterations required class I PI3Ks P110β but not components such as ATM, ATR and p53 that are involved in the DNA damage response. The siRNA-mediated depletion of the splicing regulator SRSF4, but not SRSF6, expression abrogated many of the splicing alterations as well as cell death induced by cisplatin. Many of the splicing alterations induced by cisplatin are caused by SRSF4 and they contribute to apoptosis in a process requires class I PI3K.
- Open Access
- 15 June 2008
- Published by EDP Sciences in médecine/sciences
- Vol. 24 (6-7) , 579-580
VEGF111 : Dr Jekyll et Mr Hyde ?
NOUVELLES MAGAZINE > Le VEGF (vascular endothelial growth factor) est l'un des principaux facteurs contrôlant le développement et le maintien de l'arbre vasculaire chez l'homme. Des thérapies pro-angiogènes utilisant le VEGF sont actuellement en phase d'essais précliniques et cliniques pour le traitement de pathologies très diverses [1]. C'est le cas de maladies ischémiques, pour lesquelles le bénéfice d'une revascularisation des tissus est évident, mais également d'autres pathologies associées à un déficit en VEGF comme l'éclampsie et la sclérose latérale amyotrophique. Le gène codant pour le VEGF contient 8 exons (Figure 1). Jusqu'à récemment, tous les variants décrits étaient codés par les exons 1 à 5, et différaient dans l'épissage (voir Encadré) précis des exons 6 à 8. Les exons 1 et 2 codent pour le peptide signal, impliqué dans la sécrétion de la protéine dans le milieu extracellulaire, les exons 3 et 4 pour les sites de liaison aux récepteurs et pour un site de glycosylation, et les exons 6 et 7 pour les séquences de liaison à la matrice extracellulaire et aux neuropilines. Ainsi les variants 206 et 189 sont peu biodisponibles en raison de leur liaison élevée à la matrice extracellulaire, alors que le variant 121 est actif et librement diffusible. Le variant 165 a des propriétés de liaison intermédiaires. Un variant utilisant un exon alternatif 8b présente des propriétés anti-angiogènes. L'exon 5 code pour les sites principaux de clivage par la plasmine et les métalloprotéases matricielles ([2, 3] et Iruela-Arispe, communication personnelle). Le VEGF111 Nous avons récemment cloné un nouveau variant d'épissage alternatif du VEGF,
- 15 June 2008
- Published by EDP Sciences in médecine/sciences
- Vol. 24 (6-7) , 579-580
Open AccessVEGF111 : Dr Jekyll et Mr Hyde ?
NOUVELLES MAGAZINE > Le VEGF (vascular endothelial growth factor) est l'un des principaux facteurs contrôlant le développement et le maintien de l'arbre vasculaire chez l'homme. Des thérapies pro-angiogènes utilisant le VEGF sont actuellement en phase d'essais précliniques et cliniques pour le traitement de pathologies très diverses [1]. C'est le cas de maladies ischémiques, pour lesquelles le bénéfice d'une revascularisation des tissus est évident, mais également d'autres pathologies associées à un déficit en VEGF comme l'éclampsie et la sclérose latérale amyotrophique. Le gène codant pour le VEGF contient 8 exons (Figure 1). Jusqu'à récemment, tous les variants décrits étaient codés par les exons 1 à 5, et différaient dans l'épissage (voir Encadré) précis des exons 6 à 8. Les exons 1 et 2 codent pour le peptide signal, impliqué dans la sécrétion de la protéine dans le milieu extracellulaire, les exons 3 et 4 pour les sites de liaison aux récepteurs et pour un site de glycosylation, et les exons 6 et 7 pour les séquences de liaison à la matrice extracellulaire et aux neuropilines. Ainsi les variants 206 et 189 sont peu biodisponibles en raison de leur liaison élevée à la matrice extracellulaire, alors que le variant 121 est actif et librement diffusible. Le variant 165 a des propriétés de liaison intermédiaires. Un variant utilisant un exon alternatif 8b présente des propriétés anti-angiogènes. L'exon 5 code pour les sites principaux de clivage par la plasmine et les métalloprotéases matricielles ([2, 3] et Iruela-Arispe, communication personnelle). Le VEGF111 Nous avons récemment cloné un nouveau variant d'épissage alternatif du VEGF,
- Open Access
- 17 December 2007
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 179 (6) , 1261-1273
Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents
Ultraviolet B and genotoxic drugs induce the expression of a vascular endothelial growth factor A (VEGF-A) splice variant (VEGF111) encoded by exons 1–4 and 8 in many cultured cells. Although not detected in a series of normal human and mouse tissue, VEGF111 expression is induced in MCF-7 xenografts in nude mice upon treatment by camptothecin. The skipping of exons that contain proteolytic cleavage sites and extracellular matrix–binding domains makes VEGF111 diffusible and resistant to proteolysis. Recombinant VEGF111 activates VEGF receptor 2 (VEGF-R2) and extracellularly regulated kinase 1/2 in human umbilical vascular endothelial cells and porcine aortic endothelial cells expressing VEGF-R2. The mitogenic and chemotactic activity and VEGF111's ability to promote vascular network formation during embyonic stem cell differentiation are similar to those of VEGF121 and 165. Tumors in nude mice formed by HEK293 cells expressing VEGF111 develop a more widespread network of numerous small vessels in the peritumoral tissue than those expressing other isoforms. Its potent angiogenic activity and remarkable resistance to proteolysis makes VEGF111 a potential adverse factor during chemotherapy but a beneficial therapeutic tool for ischemic diseases.
- 17 December 2007
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 179 (6) , 1261-1273
Open AccessNewly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents
Ultraviolet B and genotoxic drugs induce the expression of a vascular endothelial growth factor A (VEGF-A) splice variant (VEGF111) encoded by exons 1–4 and 8 in many cultured cells. Although not detected in a series of normal human and mouse tissue, VEGF111 expression is induced in MCF-7 xenografts in nude mice upon treatment by camptothecin. The skipping of exons that contain proteolytic cleavage sites and extracellular matrix–binding domains makes VEGF111 diffusible and resistant to proteolysis. Recombinant VEGF111 activates VEGF receptor 2 (VEGF-R2) and extracellularly regulated kinase 1/2 in human umbilical vascular endothelial cells and porcine aortic endothelial cells expressing VEGF-R2. The mitogenic and chemotactic activity and VEGF111's ability to promote vascular network formation during embyonic stem cell differentiation are similar to those of VEGF121 and 165. Tumors in nude mice formed by HEK293 cells expressing VEGF111 develop a more widespread network of numerous small vessels in the peritumoral tissue than those expressing other isoforms. Its potent angiogenic activity and remarkable resistance to proteolysis makes VEGF111 a potential adverse factor during chemotherapy but a beneficial therapeutic tool for ischemic diseases.